Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Secchiero

Showing results (21-30 of 212) with videos related to

Pageof 22
Sort By:
Anatomical Record (Hoboken, N.J. : 2007)|May 17, 2007
Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclastsErika Rimondi, Marina Zweyer, Enrico Ricci, et al.
Expert Opinion on Drug Delivery|April 9, 2019
Actively targeted nanocarriers for drug delivery to cancer cellsStefania Biffi, Rebecca Voltan, Barbara Bortot, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 15, 2012
Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cellsElisabetta Melloni, Giorgio Zauli, Claudio Celeghini, et al.
Journal of Hematology & Oncology|July 5, 2017
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerVeronica Tisato, Rebecca Voltan, Arianna Gonelli, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Journal of Leukocyte Biology|November 14, 2007
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cellsPaola Secchiero, Elisabetta Melloni, Mario Tiribelli, et al.
Journal of Cellular Physiology|October 31, 2009
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Giorgio Zauli, Erika Rimondi, Claudio Celeghini, et al.
Journal of Immunology Research|March 12, 2015
TRAIL modulates the immune system and protects against the development of diabetesFleur Bossi, Stella Bernardi, Giorgio Zauli, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 29, 2012
The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humansGianni Biolo, Paola Secchiero, Sara De Giorgi, et al.
Frontiers in Immunology|July 5, 2018
T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular ComorbiditiesFabio Casciano, Paolo D Pigatto, Paola Secchiero, et al.
Pageof 22

Showing results (21-30 of 212) with videos related to

Sort By:
Pageof 22
Anatomical Record (Hoboken, N.J. : 2007)|May 17, 2007
Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclastsErika Rimondi, Marina Zweyer, Enrico Ricci, et al.
Expert Opinion on Drug Delivery|April 9, 2019
Actively targeted nanocarriers for drug delivery to cancer cellsStefania Biffi, Rebecca Voltan, Barbara Bortot, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 15, 2012
Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cellsElisabetta Melloni, Giorgio Zauli, Claudio Celeghini, et al.
Journal of Hematology & Oncology|July 5, 2017
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerVeronica Tisato, Rebecca Voltan, Arianna Gonelli, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Journal of Leukocyte Biology|November 14, 2007
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cellsPaola Secchiero, Elisabetta Melloni, Mario Tiribelli, et al.
Journal of Cellular Physiology|October 31, 2009
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Giorgio Zauli, Erika Rimondi, Claudio Celeghini, et al.
Journal of Immunology Research|March 12, 2015
TRAIL modulates the immune system and protects against the development of diabetesFleur Bossi, Stella Bernardi, Giorgio Zauli, et al.
Clinical Nutrition (Edinburgh, Scotland)|May 29, 2012
The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humansGianni Biolo, Paola Secchiero, Sara De Giorgi, et al.
Frontiers in Immunology|July 5, 2018
T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular ComorbiditiesFabio Casciano, Paolo D Pigatto, Paola Secchiero, et al.
Pageof 22